| 1 |
35102444 | The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis. | 2022 Jun |
2 |
| 2 |
33141482 | Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. | 2021 Jul |
1 |
| 3 |
26762133 | The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. | 2017 Jan |
1 |
| 4 |
27252739 | Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis. | 2016 Jan-Apr |
2 |
| 5 |
27670281 | Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients. | 2016 Nov |
1 |
| 6 |
23079134 | Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates. | 2012 Oct 18 |
1 |
| 7 |
18226993 | Alendronate decreases TRACP 5b activity in osteoarthritic bone. | 2008 Jan 23 |
1 |
| 8 |
12631257 | Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. | 2003 Jan |
1 |